TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37728392
Drug: Breast implants
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast implants
Study: 37728696
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (including MPFF, diosmin, compression stockings, creams)
Study: 37728696
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (including MPFF)
Study: 37728787
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg) in the morning (8.00-10.00 h)
Study: 37728787
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg) in the evening (17.00-19.00 h)
Study: 37728803
Drug: Sulforaphane (SFN)
Normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane (SFN) at a daily dose of 90 mg for 24 weeks
Study: 37728907
Drug: Mirabegron (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (50 mg/d)
Study: 37728978
Drug: Thorough Epigenetic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thorough Epigenetic Marker Integration Solution (THEMIS) model using cfDNA features (methylated fragment ratio, chromosomal aneuploidy, fragment size index, fragment end motif).
Study: 37728978
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of THEMIS model with serological indicators (pepsinogen, gastrin-17, Helicobacter pylori).
Study: 37729132
Drug: Acupuncture (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (10 sessions of treatment)
Study: 37729132
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 sessions of treatment)
Study: 37729663
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/day for 8 weeks
Study: 37729663
Drug: Venlafaxine 225
Normalized name: venlafaxine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 225 mg/day for 8 weeks
Study: 37730089
Drug: Lanadelumab 150
Normalized name: Lanadelumab 150 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 150 mg every 4 weeks (Q4W) for patients aged 2 to <6 years
Study: 37730089
Drug: Lanadelumab 150
Normalized name: Lanadelumab 150 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanadelumab 150 mg every 2 weeks (Q2W) for patients aged 6 to <12 years
Study: 37730196
Drug: Benzodiazepine taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine taper with cognitive behavioral therapy (BZT + CBT)
Study: 37730196
Drug: Benzodiazepine taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine taper with health education program (BZT + HE)
Study: 37730199
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored exercise prescription (aerobic and strengthening components) supervised remotely by fitness professionals over 20 weeks
Study: 37730386
Drug: Transcutaneous auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous auricular vagus nerve stimulation (taVNS) for 7 days, twice daily for 30 minutes
Study: 37730386
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation for 7 days, twice daily for 30 minutes
Study: 37730392
Drug: Usual outpatient
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual outpatient medical treatment without rehabilitation
Study: 37730405
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with erythrosine and blue light (LED)
Study: 37730501
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/wk for 24 weeks
Study: 37730613
Drug: Chamomile tea
Normalized name: Chamomile Tea
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile tea (3 tea bags × 3 times daily)
Study: 37730613
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract capsule (3 times daily)
Study: 37730613
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule (3 times daily)
Study: 37730613
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract capsule
Study: 37730674
Drug: Post-transcriptional gene
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transcriptional gene silencing of BCL11A expression (gene therapy)
Study: 37730833
Drug: HPMC-based nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC-based nasal spray solution containing human IgG1 antibodies against SARS-CoV-2
Study: 37731023
Drug: Nofazinlimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nofazinlimab monotherapy (200 mg Q3W)
Study: 37731023
Drug: Regorafenib plus
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib plus nofazinlimab (400 mg Q6W and 200 mg Q3W)
Study: 37731086
Drug: Spesolimab 3000
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 3000 mg to W4 then 600 mg q4w
Study: 37731086
Drug: Spesolimab 3000
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 3000 mg to W4 then 300 mg q4w
Study: 37731086
Drug: Spesolimab 1500
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 1500 mg to W4 then 600 mg q4w
Study: 37731086
Drug: Spesolimab 1500
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 1500 mg to W4, 300 mg q4w to W16 then 300 mg q8w
Study: 37731086
Drug: Placebo switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo switching to spesolimab 600 mg q4w at W16
Study: 37731491
Drug: C5 inhibitor
Normalized name: Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107 )
Approvals — FDA: no, EMA: no, PMDA: no
Description: C5 inhibitor
Study: 37732080
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 to 200 mg/day)
Study: 37732619
Drug: Low-dose lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose lithium treatment
Study: 37732961
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts-extended release (MAS-ER) 80 mg/day for 10 weeks
Study: 37732961
Drug: Placebo 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 80 mg/day for 10 weeks
Study: 37732972
Drug: Mood Lifters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood Lifters for Graduate Students (ML-GS)
Study: 37732990
Drug: Aldafermin 3
Normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin 3 mg
Study: 37732990
Drug: Aldafermin 1
Normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldafermin 1 mg
Study: 37733159
Drug: Hypoglycemia (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (2.8 mmol/L, 50 mg/dL) during PM clamp
Study: 37733159
Drug: Hypoglycemia (2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia (2.8 mmol/L, 50 mg/dL) during AM clamp
Study: 37733308
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate (200 μg once daily for 14 days)
Study: 37733308
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone furoate and Placebo
Study: 37733479
Drug: iCC-SCD (digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCC-SCD (digital cognitive-behavioral therapy program)
Study: 37733724
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated mumps vaccine
Study: 37733966
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.25% ophthalmic suspension, 4 times daily for 2 months, tapered to once daily for 10 months
Study: 37733966
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 0.25% ophthalmic suspension
Study: 37733966
Drug: Historical data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical data (loteprednol 0.5% gel)
Study: 37733966
Drug: Historical data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical data (prednisolone 1% suspension)
Study: 37733977
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate and prednisone (AAP) with concomitant stereotactic body radiation therapy (SBRT)
Study: 37734399
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (three preoperative and three postoperative 3-week cycles of intravenous 50 mg/m² epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine or FLOT)
Study: 37734399
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen])
Study: 37734804
Drug: Polypill regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill regimen (5 mg ramipril, 50 mg atenolol, 12.5 mg hydrochlorothiazide, 20 mg simvastatin, 100 mg aspirin administered as two capsules once per day for 12 months)
Study: 37734804
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (tailored guideline-recommended secondary prevention medications)
Study: 37734857
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment in high HB group
Study: 37734857
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment in low HB group
Study: 37734880
Drug: Reduced-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose prednisolone (0.5 mg/kg/day) plus rituximab (375 mg/m2)
Study: 37734880
Drug: High-dose glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoids plus rituximab
Study: 37734880
Drug: Reduced-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose prednisolone plus rituximab
Study: 37734899
Drug: Suspected risk
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suspected risk factors (dialysis prescriptions, serum potassium testing frequency, patient characteristics, medication usage)
Study: 37734899
Drug: Serum potassium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum potassium levels ≥6.0 and ≥6.5 mmol/L
Study: 37735023
Drug: Individualized group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized group (n = 449) with additional 1.5 L PEG for high-risk patients
Study: 37735274
Drug: Brain insulin
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain insulin action
Study: 37735588
Drug: Adoptive transfer
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells
Study: 37735634
Drug: mFFX (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFFX (4 cycles) or Gemcitabine/Nab-Paclitaxel (6 doses)
Study: 37735634
Drug: mFFX (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFFX (2 cycles) or Gemcitabine/Nab-Paclitaxel (3 doses) + iHD-SBRT (35 to 55 Gy in 5 fractions) + mFFX (2 cycles) or Gemcitabine/Nab-Paclitaxel (3 doses)
Study: 37735634
Drug: mFFX (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFFX (4 additional cycles) or Gemcitabine/Nab-Paclitaxel (6 additional doses)
Study: 37735664
Drug: Concurrent exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent exercise training during adjuvant chemotherapy
Study: 37735668
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) (0.05 ml; cell concentration: 1.5 × 10^6 cells)
Study: 37735668
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs)
Study: 37735706
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of staff for deliberations
Study: 37735756
Drug: DC:Ad-S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC:Ad-S vaccine administered 7 to 30 days prior to stem cell collection and 20 to 34 days after ASCT
Study: 37735756
Drug: DC:Ad-S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DC:Ad-S vaccine
Study: 37736522
Drug: Daily cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cannabis use in PLWH
Study: 37736711
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone 8 mg in 500 mL normal saline
Study: 37736711
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL normal saline
Study: 37736966
Drug: Conditional-collective-community-based incentives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditional-collective-community-based incentives (C3Is) provided to community groups in HRUCs based on reduction in polio vaccine refusals.
Study: 37737962
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a (IM IFNβ-1a) exposure during early pregnancy
Study: 37737966
Drug: Naloxone nasal
Normalized name: naloxone Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone nasal spray administration by lay citizens
Study: 37738125
Drug: Nilotinib (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (230 mg/m2 twice daily)
Study: 37738368
Drug: Near-Infrared Photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near-Infrared Photobiomodulation Therapy
Study: 37738676
Drug: Immune monitoring-guided
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune monitoring-guided antiviral prophylaxis
Study: 37738676
Drug: Fixed duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed duration of antiviral prophylaxis (180 days for CMV-seronegative or 90 days for CMV-seropositive)
Study: 37739466
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (6 g) and Vitamin D
Study: 37739573
Drug: Arimoclomol 400
Normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimoclomol 400 mg three times daily (1200 mg/day) for 20 months
Study: 37739572
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg orally per day
Study: 37739939
Drug: Guadecitabine 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine 30, 45 or 60 mg/m² combined with ipilimumab
Study: 37740001
Drug: Expect Adderall/receive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expect Adderall/receive 200 mg caffeine
Study: 37740001
Drug: Expect/receive no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expect/receive no drug (control)
Study: 37740107
Drug: SRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP plus adjunctive sodium hypochlorite/amino acid and xHyA gels
Study: 37740419
Drug: Mechanical thrombectomy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical thrombectomy (MT) associated with the best medical treatment (BMT)
Study: 37740442
Drug: internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-based cognitive behaviour therapy (iCBT)
Study: 37740448
Drug: Corticosteroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone acetate 1 mL (40 mg) plus 2 mL lidocaine (1%))
Study: 37740448
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 mL saline and 2 mL lidocaine)
Study: 37740554
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, then reduced to 600 mg/day
Study: 37740874
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss treatment (BWL) for 24 weeks
Study: 37740931
Drug: Venetoclax (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (300, 600, 800, 900, or 1200 mg)
Study: 37740952
Drug: Endothelial damage
Normalized name: Head & Shoulders Damage Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial damage inhibitor (EDI)
Study: 37740952
Drug: Full electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full electrolyte solution (FES)
Study: 37741273
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg intravenously every 4 weeks, palbociclib 125 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles.
Study: 37741273
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg intravenously every 4 weeks, palbociclib 100 mg orally once daily for 3 weeks per cycle, and anastrozole 1 mg orally once daily for five 4-week cycles.
Study: 37741273
Drug: Nivolumab, palbociclib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab, palbociclib, and anastrozole (both dosage groups).
Study: 37741507
Drug: digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: digital cognitive behavioural therapy for insomnia (dCBT-I)
Study: 37741832
Drug: Atezolizumab (anti-PD-L1)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (anti-PD-L1) therapy
Study: 37742328
Drug: Statin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin plus ascorbic acid (atorvastatin 80-mg the day before, atorvastatin 40-mg two hours before, and atorvastatin 40-mg for two days after CECT; plus ascorbic acid 500 mg)
Study: 37742328
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets of placebo once/daily before the procedure and for another 3 days)
Study: 37742653
Drug: Network Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network Medicine approach to redefine dementia treatment
Study: 37742734
Drug: Drug-eluting device
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting device treatment
Study: 37742797
Drug: High-dose carotenoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose carotenoid juice intervention (12 ounces juice, 8 mg total carotenoids/d)
Study: 37742797
Drug: Moderate-dose carotenoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose carotenoid juice intervention (6 ounces juice, 4 mg total carotenoids/d)
Study: 37742797
Drug: Other variables
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other variables (self-categorized race/ethnicity, biological sex, baseline body fat, body mass index, skin melanin, sun exposure)
Study: 37742911
Drug: Aprocitentan, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan, a dual endothelin-1 receptor antagonist
Study: 37743037
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, then every 8 weeks), adalimumab (160 mg on day 2, 80 mg at week 2, then 40 mg every 2 weeks), and methotrexate (15 mg weekly)
Study: 37743180
Drug: Selinexor dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor dose reductions (median dose 71.4 mg/wk)
Study: 37743486
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) administered at a continuous infusion rate of 0.2 µg/kg/h until the end of dural closure.
Study: 37743486
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control group) administered in an identical volume and setting.
Study: 37743489
Drug: Green-MED diet
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green-MED diet (including green tea 3-4 cups/day and Mankai 500-ml green shake)
Study: 37743489
Drug: Mediterranean (MED)
Normalized name: Thynnus mediterraneus flesh
DrugBank: Northern bluefin tuna (DB14162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean (MED) diet (including 28 g walnuts/day)
Study: 37744662
Drug: Benzodiazepine administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzodiazepine administration during cardiac surgery
Study: 37745024
Drug: sIPV (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: sIPV (inactivated poliovirus vaccine derived from the Sabin strain)
Study: 37745024
Drug: wIPV (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: wIPV (inactivated poliovirus vaccine derived from wild strain)